Research

Clinical trials

Every amyloidosis study now recruiting, about to open, or enrolling by invitation, anywhere in the world, listed straight from ClinicalTrials.gov and refreshed every day.

Information, not medical advice. The Alliance does not run these studies and cannot enrol you in one. If a trial looks relevant, discuss it with the doctor who follows your amyloidosis.

Recruiting and upcoming studies

The list covers AL, ATTR and AA amyloidosis as well as cerebral amyloid angiopathy. Each card says where the study stands: open to anyone who meets its criteria, not yet open, or restricted to people the investigators invite. Studies that close simply leave the list.

Showing 13–24 of 202 trials

Not yet recruitingAL (light chain)

Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis (opens on ClinicalTrials.gov)

This study is researching a Regeneron drug called linvoseltamab ("study drug") alone compared to standard of care (SoC) combination to see if it can…

Study
Interventional (treatment)
Phase
Phase 3
Sponsor
Regeneron Pharmaceuticals

No study locations listed yet

NCT07901725Updated 28 October 2026

Not yet recruitingATTR (transthyretin)

Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor (opens on ClinicalTrials.gov)

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid in the heart muscle. This…

Study
Observational (registry, imaging)
Sponsor
Bayer

Recruiting in: AustriaGermanyItaly

NCT07557147Updated 26 October 2026

RecruitingATTR (transthyretin)

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis (opens on ClinicalTrials.gov)

This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with…

Study
Interventional (treatment)
Phase
Phase 3
Sponsor
Novo Nordisk A/S

Recruiting in: ArgentinaAustraliaBelgiumBrazil+16

NCT07207811Updated 21 October 2026

RecruitingATTR (transthyretin)

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis (opens on ClinicalTrials.gov)

Transthyretin (TTR) is a protein made by the liver that helps transport thyroid hormone and vitamin A in the blood. In some people, this…

Study
Interventional (treatment)
Phase
Phase 4
Sponsor
Bayer

Recruiting in: AustriaBelgiumGermanyItaly+1

NCT07298044Updated 15 October 2026

This list only covers amyloidosis studies that are open or about to open. The registry holds every study, including those already completed.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). List last retrieved on 7 November 2026. clinicaltrials.gov

Not sure where to start?

Our member associations know the teams running these studies in their own country, and can help you prepare the conversation with your doctor.